FDA advisers back wider use of Abbott's Humira
WASHINGTON (Reuters) - Abbott Laboratories Inc won a U.S. panel's support on Tuesday for wider use of its blockbuster Humira drug in a type of inflammatory bowel disease. A panel of outside advisers to the Food and Drug Administration voted 15 to 2 that the benefits of Humira outweighed its risks in treating ulcerative colitis. The drug is already approved for six other conditions. The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by the end of the year. ...
Source: news.yahoo.com
No comments:
Post a Comment